Compounds > ethylisopropylamiloride
Page last updated: 2024-10-21

ethylisopropylamiloride and ER-Negative PR-Negative HER2-Negative Breast Cancer

ethylisopropylamiloride has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

ethylisopropylamiloride: structure in first source
ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Balza, E1
Carlone, S1
Carta, S1
Piccioli, P1
Cossu, V1
Marini, C1
Sambuceti, G1
Rubartelli, A1
Castellani, P1

Other Studies

1 other study available for ethylisopropylamiloride and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.
    Cancer medicine, 2022, Volume: 11, Issue:1

    Topics: Amiloride; Animals; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell

2022